Advanced
  Home Compare Reports

Comparison with Similar Reports

Molecular Quality Controls Market by Product (Independent, Instrument Specific (PCR, DNA Sequencing)), Application (Infectious Diseases Diagnostic), A...

Publisher:        MarketsandMarkets

# of Pages:        268

Rating: 

1 User License $4,950

Publication Date:  February, 2022

Price:       $4,950 / User License




1 INTRODUCTION 29
1.1 OBJECTIVES OF THE STUDY 29
1.2 MARKET DEFINITION 29
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 30
1.3 MARKET SCOPE 31
1.3.1 MARKETS COVERED 31
1.3.2 YEARS CONSIDERED FOR THE STUDY 32
1.4 CURRENCY 32
TABLE 1 STANDARD CURRENCY CONVERSION RATES 32
1.5 LIMITATIONS 33
1.6 STAKEHOLDERS 33
1.7 SUMMARY OF CHANGES 33
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
FIGURE 1 RESEARCH DESIGN 35
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 36
2.1.2 SECONDARY RESEARCH 37
2.1.3 PRIMARY DATA 38
FIGURE 2 PRIMARY SOURCES 38
2.1.3.1 Key data from primary sources 39
FIGURE 3 INSIGHTS FROM INDUSTRY EXPERTS 39
2.1.3.2 Breakdown of primary sources 40
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 40
FIGURE 5 PRIMARY SOURCES 40
2.2 MARKET SIZE ESTIMATION 41
2.2.1 BOTTOM-UP APPROACH 42
FIGURE 6 MOLECULAR QUALITY CONTROLS MARKET: BOTTOM-UP APPROACH 42
2.2.2 TOP-DOWN APPROACH 43
FIGURE 7 MOLECULAR QUALITY CONTROLS MARKET: TOP-DOWN APPROACH 43
FIGURE 8 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 44
FIGURE 9 SUPPLY-SIDE MARKET SIZE ESTIMATION: MOLECULAR
QUALITY CONTROLS MARKET (2020) 44
FIGURE 10 MARKET SIZE ESTIMATION: PARENT MARKET 45
FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 46
FIGURE 12 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MOLECULAR QUALITY CONTROLS MARKET (2021–2026) 47
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 48
FIGURE 13 DATA TRIANGULATION METHODOLOGY 48
2.4 MARKET SHARE ESTIMATION 49
2.5 ASSUMPTIONS FOR THE STUDY 49
2.6 RISK ASSESSMENT 50
TABLE 2 RISK ASSESSMENT: MOLECULAR QUALITY CONTROLS MARKET 50
2.7 COVID-19 HEALTH ASSESSMENT 50
2.8 COVID-19 ECONOMIC ASSESSMENT 50
2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 51
FIGURE 14 CRITERIA IMPACTING THE GLOBAL ECONOMY 51
FIGURE 15 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 52
2.10 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE MOLECULAR QUALITY CONTROLS MARKET 53
3 EXECUTIVE SUMMARY 54
FIGURE 16 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2021 VS. 2026 (USD MILLION) 54
FIGURE 17 MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE,
2021 VS. 2026 (USD MILLION) 55
FIGURE 18 MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2021 VS. 2026 (USD MILLION) 55
FIGURE 19 MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2021 VS. 2026 (USD MILLION) 56
FIGURE 20 GEOGRAPHICAL SNAPSHOT OF THE MOLECULAR
QUALITY CONTROLS MARKET 57
4 PREMIUM INSIGHTS 58
4.1 MOLECULAR QUALITY CONTROLS: MARKET OVERVIEW 58
FIGURE 21 INCREASING GOVERNMENT FUNDING TO SUPPORT
GENOMICS PROJECTS TO DRIVE MARKET GROWTH 58
4.2 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT 59
FIGURE 22 INSTRUMENT-SPECIFIC CONTROLS SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD (2021–2026) 59
4.3 APAC: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION
AND COUNTRY (2020) 60
FIGURE 23 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE APAC MOLECULAR QUALITY CONTROLS
MARKET IN 2020 60
4.4 MOLECULAR QUALITY CONTROLS MARKET: GEOGRAPHIC MIX 61
FIGURE 24 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 61
4.5 MOLECULAR QUALITY CONTROLS MARKET: DEVELOPED VS. DEVELOPING MARKETS 62
FIGURE 25 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATE DURING THE FORECAST PERIOD 62
 
5 MARKET OVERVIEW 63
5.1 INTRODUCTION 63
FIGURE 26 MOLECULAR QUALITY CONTROLS MARKET: DRIVERS,
RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 63
5.1.1 DRIVERS 64
5.1.1.1 Increasing number of accredited clinical laboratories 64
FIGURE 27 NUMBER OF LABORATORIES THAT RECEIVED CLIA ACCREDITATION,
BY ACCREDITATION ORGANIZATION (2021) 64
5.1.1.2 Growing adoption of third-party quality controls 65
5.1.1.3 Increasing government funding to support genomics projects 65
TABLE 3 GOVERNMENT FUNDING TO SUPPORT GENOMICS 66
5.1.1.4 Increasing demand for personalized medicines and declining
costs of sequencing procedures 66
FIGURE 28 COST OF SEQUENCING PROCEDURES, 2016-2021 67
5.1.1.5 Increasing prevalence of infectious diseases, cancer, &
genetic diseases 67
FIGURE 29 GLOBAL CANCER INCIDENCE, 2020 VS. 2024 68
5.1.1.6 Rising demand for external quality assessment support 68
5.1.2 RESTRAINTS 69
5.1.2.1 Additional costs involved in quality control and budget
constraints in hospitals and laboratories 69
5.1.2.2 Unfavorable reimbursement scenario for molecular tests 69
5.1.3 OPPORTUNITIES 69
5.1.3.1 Rising demand for multi-analyte controls 69
5.1.3.2 Growth opportunities in emerging countries 70
5.1.4 CHALLENGES 70
5.1.4.1 Lack of mandatory regulations for clinical laboratory
accreditation in several emerging countries 70
5.1.4.2 Changing regulatory framework 71
6 INDUSTRY INSIGHTS 72
6.1 INDUSTRY TRENDS 72
6.1.1 INCREASING DEMAND FOR THIRD-PARTY INDEPENDENT QUALITY CONTROLS 72
TABLE 4 THIRD-PARTY INDEPENDENT QUALITY CONTROLS OFFERED
BY KEY MARKET PLAYERS 72
6.1.2 CONSOLIDATION OF LABORATORIES 73
6.2 PRICING ANALYSIS 73
TABLE 5 PRICING ANALYSIS OF MOLECULAR QUALITY CONTROL PRODUCTS (2021) 73
FIGURE 30 MOLECULAR QUALITY CONTROL PATENT PUBLICATION TRENDS (JANUARY 2012-JANUARY 2022) 74
FIGURE 31 MOLECULAR QUALITY CONTROLS: TOP 10 COMPANIES WITH THE HIGHEST PATENT APPLICATIONS (2011-2020) 75
FIGURE 32 MOLECULAR QUALITY CONTROLS: TOP 10 PATENT OWNERS (2011-2020) 75
 
6.3 VALUE CHAIN ANALYSIS 76
FIGURE 33 VALUE CHAIN ANALYSIS 76
6.4 SUPPLY CHAIN ANALYSIS 76
FIGURE 34 SUPPLY CHAIN ANALYSIS 77
6.5 ECOSYSTEM ANALYSIS 77
6.6 PORTER’S FIVE FORCES ANALYSIS 78
TABLE 6 MOLECULAR QUALITY CONTROLS MARKET:
PORTER’S FIVE FORCES ANALYSIS 78
6.6.1 THREAT OF NEW ENTRANTS 78
6.6.2 THREAT OF SUBSTITUTES 78
6.6.3 BARGAINING POWER OF BUYERS 78
6.6.4 BARGAINING POWER OF SUPPLIERS 79
6.6.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS 79
6.7 REGULATORY ANALYSIS 79
6.7.1 NORTH AMERICA 79
6.7.1.1 US 79
TABLE 7 US: CLASSIFICATION OF QUALITY CONTROL MATERIAL 80
6.7.1.2 Canada 80
6.7.2 EUROPE 80
TABLE 8 EUROPE: ACCREDITATION BODIES FOR MEDICAL LABORATORIES 81
6.7.3 ASIA PACIFIC 81
6.7.3.1 Japan 81
6.7.3.2 China 82
6.7.3.3 India 82
6.8 TRENDS & DISRUPTIONS AFFECTING CUSTOMERS’ BUSINESS 82
FIGURE 35 MOLECULAR QUALITY CONTROLS MARKET: TRENDS & DISRUPTIONS AFFECTING CUSTOMERS’ BUSINESSES 82
6.8.1 COVID-19 IMPACT ANALYSIS 83
7 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT 86
7.1 INTRODUCTION 87
FIGURE 36 INDEPENDENT CONTROLS SEGMENT TO DOMINATE THE MOLECULAR QUALITY CONTROLS MARKET IN 2026 87
TABLE 9 QUALITY CONTROLS FOR MOLECULAR DIAGNOSTICS OFFERED BY KEY MARKET PLAYERS 88
TABLE 10 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 89
7.2 INDEPENDENT CONTROLS 89
7.2.1 A WIDE RANGE OF APPLICATIONS AND REDUCTIONS IN OPERATIONAL COSTS HAVE BOOSTED THE ADOPTION OF INDEPENDENT CONTROLS 89
TABLE 11 INDEPENDENT MOLECULAR QUALITY CONTROLS OFFERED
BY KEY MARKET PLAYERS 90
TABLE 12 INDEPENDENT MOLECULAR QUALITY CONTROLS MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 90
7.3 INSTRUMENT-SPECIFIC CONTROLS 91
TABLE 13 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 91
TABLE 14 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS MARKET,
BY TECHNOLOGY, 2019–2026 (USD MILLION) 92
7.3.1 POLYMERASE CHAIN REACTION (PCR) 92
7.3.1.1 Growing use of PCR in proteomics and genomics is a major factor driving market growth 92
TABLE 15 PCR MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 93
7.3.2 DNA SEQUENCING & NGS 93
7.3.2.1 Advancements in sequencing technologies to support market growth 93
TABLE 16 DNA SEQUENCING & NGS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 94
7.3.3 OTHER TECHNOLOGIES 94
TABLE 17 OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 95
8 MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE 96
8.1 INTRODUCTION 97
FIGURE 37 SINGLE-ANALYTE CONTROLS SEGMENT DOMINATES THE MOLECULAR QUALITY CONTROLS MARKET 97
TABLE 18 MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE,
2019–2026 (USD MILLION) 97
8.2 SINGLE-ANALYTE CONTROLS 98
8.2.1 SIGNIFICANT USE OF SINGLEPLEX ASSAYS IN HOSPITALS IS A KEY FACTOR DRIVING MARKET GROWTH 98
TABLE 19 SINGLE-ANALYTE MOLECULAR QUALITY CONTROLS MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 98
8.3 MULTI-ANALYTE CONTROLS 99
8.3.1 INCREASING PREFERENCE FOR MULTI-ANALYTE CONTROLS TO
FUEL MARKET GROWTH 99
TABLE 20 EXAMPLES OF MULTI-ANALYTE CONTROLS 99
TABLE 21 MULTI-ANALYTE MOLECULAR QUALITY CONTROLS MARKET,
BY COUNTRY, 2019–2026 (USD MILLION) 100
9 MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION 101
9.1 INTRODUCTION 102
FIGURE 38 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO DOMINATE THE MOLECULAR QUALITY CONTROLS MARKET DURING THE FORECAST PERIOD 102
TABLE 22 MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 103
9.2 INFECTIOUS DISEASE DIAGNOSTICS 103
9.2.1 GROWING FOCUS ON PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH 103
TABLE 23 NUMBER OF COVID-19 CASES, BY COUNTRY (2021) 104
TABLE 24 MOLECULAR QUALITY CONTROLS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD MILLION) 105
 
9.3 ONCOLOGY TESTING 105
9.3.1 ONCOLOGY TESTING SEGMENT IS PROJECTED TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 105
TABLE 25 MOLECULAR QUALITY CONTROLS MARKET FOR ONCOLOGY TESTING,
BY COUNTRY, 2019–2026 (USD MILLION) 106
9.4 GENETIC TESTING 106
9.4.1 ADVANCEMENTS IN GENETIC TESTING TO DRIVE MARKET GROWTH 106
TABLE 26 MOLECULAR QUALITY CONTROLS MARKET FOR GENETIC TESTING,
BY COUNTRY, 2019–2026 (USD MILLION) 107
9.5 OTHER APPLICATIONS 107
TABLE 27 MOLECULAR QUALITY CONTROLS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2019–2026 (USD MILLION) 108
10 MOLECULAR QUALITY CONTROLS MARKET, BY END USER 109
10.1 INTRODUCTION 110
FIGURE 39 DIAGNOSTIC LABORATORIES SEGMENT TO REGISTER
THE HIGHEST GROWTH IN THE FORECAST PERIOD 110
TABLE 28 MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 110
10.2 DIAGNOSTIC LABORATORIES 111
10.2.1 INCREASING NUMBER OF ACCREDITED DIAGNOSTIC LABORATORIES TO PROVIDE GROWTH OPPORTUNITIES IN THE COMING YEARS 111
TABLE 29 MOLECULAR QUALITY CONTROLS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION) 112
10.3 HOSPITALS 112
10.3.1 GROWING PATIENT VOLUME IS DRIVING THE ADOPTION OF MOLECULAR QUALITY CONTROLS AMONG HOSPITALS 112
TABLE 30 MOLECULAR QUALITY CONTROLS MARKET FOR HOSPITALS, BY COUNTRY, 2019–2026 (USD MILLION) 113
10.4 IVD MANUFACTURERS & CONTRACT RESEARCH ORGANIZATIONS 114
10.4.1 ADVANCEMENTS IN MOLECULAR TECHNOLOGIES
TO SUPPORT MARKET GROWTH 114
TABLE 31 MOLECULAR QUALITY CONTROLS MARKET FOR IVD MANUFACTURERS & CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,
2019–2026 (USD MILLION) 114
10.5 ACADEMIC & RESEARCH INSTITUTES 115
10.5.1 RISING FOCUS ON ACCURATE RESEARCH RESULTS
TO DRIVE MARKET GROWTH 115
TABLE 32 MOLECULAR QUALITY CONTROLS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION) 115
10.6 OTHER END USERS 116
TABLE 33 MOLECULAR QUALITY CONTROLS MARKET FOR OTHER END USERS,
BY COUNTRY, 2019–2026 (USD MILLION) 116
 
11 MOLECULAR QUALITY CONTROLS MARKET, BY REGION 117
11.1 INTRODUCTION 118
TABLE 34 MOLECULAR QUALITY CONTROLS MARKET, BY REGION,
2019–2026 (USD MILLION) 118
11.2 NORTH AMERICA 118
FIGURE 40 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET SNAPSHOT 119
TABLE 35 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 120
TABLE 36 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 120
TABLE 37 NORTH AMERICA: INSTRUMENT-SPECIFIC CONTROLS MARKET,
BY TECHNOLOGY, 2019–2026 (USD MILLION) 120
TABLE 38 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION) 121
TABLE 39 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 121
TABLE 40 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET,
BY END USER, 2019–2026 (USD MILLION) 121
11.2.1 US 122
11.2.1.1 Increasing CLIA accreditation for clinical laboratories is driving the market for molecular quality controls in the US 122
FIGURE 41 US: NUMBER OF LABORATORIES WITH CLIA ACCREDITATION,
BY ORGANIZATION (2018) 122
TABLE 41 US: KEY MACROINDICATORS 123
TABLE 42 US: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 123
TABLE 43 US: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 123
TABLE 44 US: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE,
2019–2026 (USD MILLION) 124
TABLE 45 US: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 124
TABLE 46 US: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 124
11.2.2 CANADA 125
11.2.2.1 Canada has a well-established and well-funded
biomedical research sector 125
TABLE 47 CANADA: KEY MACROINDICATORS 125
TABLE 48 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 126
TABLE 49 CANADA: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 126
TABLE 50 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION) 126
TABLE 51 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 127
TABLE 52 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 127
11.3 EUROPE 127
FIGURE 42 EUROPE: CANCER PREVALENCE, BY COUNTRY 128
TABLE 53 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 129
TABLE 54 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 129
TABLE 55 EUROPE: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 129
TABLE 56 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION) 130
TABLE 57 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 130
TABLE 58 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 130
11.3.1 GERMANY 131
11.3.1.1 Increasing number of certified laboratories and the rising volume of high-quality tests performed by these laboratories to support market growth in Germany 131
TABLE 59 GERMANY: KEY MACROINDICATORS 131
TABLE 60 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 132
TABLE 61 GERMANY: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 132
TABLE 62 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION) 132
TABLE 63 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 133
TABLE 64 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 133
11.3.2 FRANCE 134
11.3.2.1 Increasing prevalence of infectious diseases and growing demand for early diagnosis to drive market growth 134
TABLE 65 FRANCE: KEY MACROINDICATORS 134
TABLE 66 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 134
TABLE 67 FRANCE: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 135
TABLE 68 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION) 135
TABLE 69 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 135
TABLE 70 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 136
11.3.3 UK 136
11.3.3.1 Growth in the life science industry and increased research to drive market growth in the UK 136
TABLE 71 UK: KEY MACROINDICATORS 137
TABLE 72 UK: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 137
TABLE 73 UK: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 138
TABLE 74 UK: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE,
2019–2026 (USD MILLION) 138
TABLE 75 UK: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 138
TABLE 76 UK: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 139
11.3.4 ITALY 139
11.3.4.1 Growing disease prevalence to drive the demand for better and more accurate disease diagnosis in Italy 139
TABLE 77 ITALY: KEY MACROINDICATORS 140
TABLE 78 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 140
TABLE 79 ITALY: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 140
TABLE 80 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE,
2019–2026 (USD MILLION) 141
TABLE 81 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 141
TABLE 82 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 141
11.3.5 SPAIN 142
11.3.5.1 Increasing demand for prenatal and genetic testing and rising focus on laboratory consolidation to support market growth in Spain 142
TABLE 83 SPAIN: KEY MACROINDICATORS 143
TABLE 84 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 143
TABLE 85 SPAIN: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 143
TABLE 86 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE,
2019–2026 (USD MILLION) 144
TABLE 87 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 144
TABLE 88 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 144
11.3.6 RUSSIA 145
11.3.6.1 Increasing acceptance of molecular diagnostics-based personalized medicine to drive market growth 145
TABLE 89 RUSSIA: DISEASE STATISTICS (2020) 145
TABLE 90 RUSSIA: POPULATION AND CANCER STATISTICS 145
TABLE 91 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 145
TABLE 92 RUSSIA: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 146
TABLE 93 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION) 146
TABLE 94 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 146
TABLE 95 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 147
11.3.7 REST OF EUROPE 147
TABLE 96 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 147
TABLE 97 REST OF EUROPE: INSTRUMENT-SPECIFIC CONTROLS MARKET,
BY TECHNOLOGY, 2019–2026 (USD MILLION) 148
TABLE 98 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION) 148
TABLE 99 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 148
TABLE 100 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION) 149
11.4 ASIA PACIFIC 149
FIGURE 43 ASIA PACIFIC: CANCER PREVALENCE 150
FIGURE 44 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET SNAPSHOT 151
TABLE 101 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 152
TABLE 102 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 152
TABLE 103 ASIA PACIFIC: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 152
TABLE 104 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION) 153
TABLE 105 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 153
TABLE 106 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION) 153
11.4.1 JAPAN 154
11.4.1.1 Well-developed healthcare system and the rising demand for improvements in the quality of IVD test results to drive market growth in Japan 154
TABLE 107 JAPAN: KEY MACROINDICATORS 154
TABLE 108 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 154
TABLE 109 JAPAN: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 155
TABLE 110 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE,
2019–2026 (USD MILLION) 155
TABLE 111 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 155
TABLE 112 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 156
11.4.2 CHINA 156
11.4.2.1 Growing access to modern healthcare and government support to boost the market growth in China 156
TABLE 113 CHINA: KEY MACROINDICATORS 157
TABLE 114 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 157
TABLE 115 CHINA: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 157
TABLE 116 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE,
2019–2026 (USD MILLION) 158
TABLE 117 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 158
TABLE 118 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 158
11.4.3 INDIA 159
11.4.3.1 Rising need to secure NABL accreditations to drive the demand for quality controls in India 159
FIGURE 45 INDIA: INCREASING NUMBER OF LABS WITH NABL ACCREDITATIONS,
2012–2020 159
TABLE 119 INDIA: KEY MACROINDICATORS 160
TABLE 120 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 160
TABLE 121 INDIA: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION) 160
TABLE 122 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE,
2019–2026 (USD MILLION) 161
TABLE 123 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 161
TABLE 124 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER,
2019–2026 (USD MILLION) 161
11.4.4 REST OF ASIA PACIFIC 162
TABLE 125 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 163
TABLE 126 REST OF ASIA PACIFIC: INSTRUMENT-SPECIFIC CONTROLS MARKET,
BY TECHNOLOGY, 2019–2026 (USD MILLION) 163
TABLE 127 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET,
BY ANALYTE TYPE, 2019–2026 (USD MILLION) 163
TABLE 128 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 164
TABLE 129 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET,
BY END USER, 2019–2026 (USD MILLION) 164
11.5 LATIN AMERICA 165
11.5.1 RISING INCIDENCE OF SEVERAL INFECTIOUS DISEASES TO
DRIVE MARKET GROWTH 165
TABLE 130 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 166
TABLE 131 LATIN AMERICA: INSTRUMENT-SPECIFIC CONTROLS MARKET,
BY TECHNOLOGY, 2019–2026 (USD MILLION) 166
TABLE 132 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION) 166
TABLE 133 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 167
TABLE 134 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION) 167
11.6 MIDDLE EAST & AFRICA 168
11.6.1 GROWING GOVERNMENT INITIATIVES TO IMPROVE HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET GROWTH 168
TABLE 135 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET,
BY PRODUCT, 2019–2026 (USD MILLION) 168
TABLE 136 MIDDLE EAST & AFRICA: INSTRUMENT-SPECIFIC CONTROLS MARKET,
BY TECHNOLOGY, 2019–2026 (USD MILLION) 169
TABLE 137 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET,
BY ANALYTE TYPE, 2019–2026 (USD MILLION) 169
TABLE 138 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET,
BY APPLICATION, 2019–2026 (USD MILLION) 169
TABLE 139 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET,
BY END USER, 2019–2026 (USD MILLION) 170
12 COMPETITIVE LANDSCAPE 171
12.1 MARKET OVERVIEW 171
12.2 KEY PLAYER STRATEGIES 172
12.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 173
12.4 MARKET RANKING ANALYSIS 174
FIGURE 47 RANK OF COMPANIES IN THE GLOBAL MOLECULAR QUALITY CONTROLS MARKET (2020) 174
12.5 COMPETITIVE LEADERSHIP MAPPING 175
12.5.1 STARS 176
12.5.2 EMERGING LEADERS 176
12.5.3 PERVASIVE PLAYERS 176
12.5.4 PARTICIPANTS 176
FIGURE 48 MOLECULAR QUALITY CONTROLS MARKET: COMPETITIVE LEADERSHIP MAPPING (2020) 177
12.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2020) 178
12.6.1 PROGRESSIVE COMPANIES 178
12.6.2 STARTING BLOCKS 178
12.6.3 RESPONSIVE COMPANIES 178
12.6.4 DYNAMIC COMPANIES 178
FIGURE 49 MOLECULAR QUALITY CONTROLS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2020) 179
12.7 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF THE TOP PLAYERS 180
FIGURE 50 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE MOLECULAR QUALITY CONTROLS MARKET 180
12.8 COMPANY GEOGRAPHIC FOOTPRINT 181
12.8.1 GEOGRAPHIC REVENUE MIX: KEY PLAYERS 181
TABLE 140 COMPANY END-USER FOOTPRINT (20 COMPANIES) 182
TABLE 141 COMPANY REGIONAL FOOTPRINT (20 COMPANIES) 183
12.9 COMPETITIVE SITUATION AND TRENDS 184
12.9.1 MOLECULAR QUALITY CONTROLS MARKET: PRODUCT LAUNCHES & REGULATORY APPROVALS 184
TABLE 142 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS 184
12.9.2 MOLECULAR QUALITY CONTROLS MARKET: KEY DEALS 186
TABLE 143 KEY DEALS 186
13 COMPANY PROFILES 190
13.1 KEY PLAYERS 190
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 LGC LIMITED 190
TABLE 144 LGC LIMITED: BUSINESS OVERVIEW 190
FIGURE 51 LCG LIMITED: COMPANY SNAPSHOT (2021) 191
13.1.2 THERMO FISHER SCIENTIFIC 197
TABLE 145 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 197
FIGURE 52 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020) 198
13.1.3 BIO-RAD LABORATORIES, INC. 204
TABLE 146 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 204
FIGURE 53 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020) 205
13.1.4 MICROBIOLOGICS, INC. 209
TABLE 147 MICROBIOLOGICS, INC.: BUSINESS OVERVIEW 209
13.1.5 ABBOTT LABORATORIES 215
TABLE 148 ABBOTT LABORATORIES: BUSINESS OVERVIEW 215
FIGURE 54 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020) 216
13.2 OTHER PLAYERS 219
13.2.1 ROCHE DIAGNOSTICS 219
TABLE 149 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW 219
FIGURE 55 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2020) 220
13.2.2 ZEPTOMETRIX, LLC 223
TABLE 150 ZEPTOMETRIX, LLC: BUSINESS OVERVIEW 223
13.2.3 QUIDEL CORPORATION 229
TABLE 151 QUIDEL CORPORATION: BUSINESS OVERVIEW 229
FIGURE 56 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021) 230
13.2.4 QNOSTICS 232
TABLE 152 QNOSTICS: BUSINESS OVERVIEW 232
13.2.5 MAINE MOLECULAR QUALITY CONTROLS, INC. 236
TABLE 153 MAINE MOLECULAR QUALITY CONTROLS, INC.: BUSINESS OVERVIEW 236
13.2.6 RANDOX LABORATORIES LTD. 239
TABLE 154 RANDOX LABORATORIES LTD.: BUSINESS OVERVIEW 239
13.2.7 BIO-TECHNE CORPORATION 242
TABLE 155 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW 242
FIGURE 57 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2021) 243
13.2.8 FORTRESS DIAGNOSTICS 245
TABLE 156 FORTRESS DIAGNOSTICS: BUSINESS OVERVIEW 245
13.2.9 MICROBIX BIOSYSTEMS 247
TABLE 157 MICROBIX BIOSYSTEMS: BUSINESS OVERVIEW 247
FIGURE 58 MICROBIX BIOSYSTEMS: COMPANY SNAPSHOT (2021) 248
13.2.10 GRIFOLS, S.A. 252
TABLE 158 GRIFOLS, S.A.: BUSINESS OVERVIEW 252
FIGURE 59 GRIFOLS, S.A.: COMPANY SNAPSHOT (2020) 253
13.2.11 ORTHO CLINICAL DIAGNOSTICS 255
TABLE 159 ORTHO CLINICAL DIAGNOSTICS: BUSINESS OVERVIEW 255
FIGURE 60 ORTHO CLINICAL DIAGNOSTICS: COMPANY SNAPSHOT (2020) 256
13.2.12 ANCHOR MOLECULAR 258
TABLE 160 ANCHOR MOLECULAR: BUSINESS OVERVIEW 258
13.2.13 SPEEDX PTY. LTD. 259
TABLE 161 SPEEDX PTY. LTD.: BUSINESS OVERVIEW 259
13.2.14 SERO AS 262
TABLE 162 SERO AS: BUSINESS OVERVIEW 262
13.2.15 SEEGENE INC. 263
TABLE 163 SEEGENE INC.: BUSINESS OVERVIEW 263
FIGURE 61 SEEGENE INC: COMPANY SNAPSHOT (2020) 264
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX 268
14.1 DISCUSSION GUIDE 268
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 272
14.3 AVAILABLE CUSTOMIZATIONS 274
14.4 RELATED REPORTS 274
14.5 AUTHOR DETAILS 275

Lateral Flow Assay Components Market by Type, Application Type (Clinical Testing (Infectious, Cardiac Marker Test) Veterinary, Food Safety), Technique...

Publisher:        MarketsandMarkets

# of Pages:        224

Rating: 

1 User License $4,950

Publication Date:  April, 2022

Price:       $4,950 / User License




1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.2.1 CATEGORY-WISE INCLUSIONS AND EXCLUSIONS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 33
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
FIGURE 1 LATERAL FLOW ASSAY COMPONENTS MARKET SEGMENTATION 34
1.3.2 YEARS CONSIDERED FOR THE STUDY 35
1.4 CURRENCY 35
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 35
1.5 STAKEHOLDERS 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH APPROACH 36
FIGURE 2 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 37
2.1.2 PRIMARY DATA 38
2.1.2.1 Primary sources 38
2.1.2.2 Key data from primary sources 39
2.1.2.3 Breakdown of primaries 39
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE):
BY COMPANY TYPE, DESIGNATION, AND REGION 39
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 40
2.2 MARKET SIZE ESTIMATION 40
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021) 41
FIGURE 6 SUPPLY-SIDE ANALYSIS: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 42
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 44
FIGURE 7 DATA TRIANGULATION METHODOLOGY 45
2.4 KEY INDUSTRY INSIGHTS 46
2.5 LIMITATIONS 46
2.5.1 METHODOLOGY-RELATED LIMITATIONS 46
2.6 RISK ASSESSMENT 47
2.7 ASSUMPTIONS FOR THE STUDY 47
 
3 EXECUTIVE SUMMARY 48
FIGURE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 48
FIGURE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2022 VS. 2027 (USD MILLION) 49
FIGURE 10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 50
FIGURE 11 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 51
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 52
4 PREMIUM INSIGHTS 53
4.1 LATERAL FLOW ASSAY COMPONENTS MARKET OVERVIEW 53
FIGURE 13 RISING NUMBER OF LOCAL MANUFACTURERS FOR COMPONENTS IS DRIVING THE GROWTH OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 53
4.2 REGIONAL MIX: LATERAL FLOW ASSAY COMPONENTS MARKET 54
FIGURE 14 APAC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 54
4.3 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE AND COUNTRY 55
FIGURE 15 MEMBRANES ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021 55
4.4 LATERAL FLOW ASSAY COMPONENTS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 56
4.5 LATERAL FLOW ASSAY COMPONENTS MARKET: DEVELOPED VS. DEVELOPING COUNTRIES 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS: IMPACT ANALYSIS 57
5.2.1 DRIVERS 58
5.2.1.1 Growing demand for lateral flow assay kits due
to the COVID-19 pandemic 58
5.2.1.2 Growing usage of home-based lateral flow assay devices 58
5.2.1.3 Growing demand for point-of-care testing 58
5.2.1.4 Increasing public-private investments to develop lateral flow assays 59
5.2.2 RESTRAINTS 59
5.2.2.1 Availability of alternative diagnostic technologies 59
5.2.3 OPPORTUNITIES 59
5.2.3.1 Evolving applications of lateral flow assays 59
5.2.4 CHALLENGES 60
5.2.4.1 Requirement of specialized storage and shipping facilities for membranes 60
5.3 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES (YC-YCC) IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
FIGURE 16 YC–YCC SHIFT IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 61
5.5 AVERAGE SELLING PRICE TREND 61
TABLE 2 AVERAGE SELLING PRICE OF LATERAL FLOW ASSAY COMPONENTS,
BY REGION, 2021 (USD) 61
5.6 ECOSYSTEM MARKET MAP 62
FIGURE 17 ECOSYSTEM: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 62
5.7 PATENT ANALYSIS 63
5.7.1 PATENT PUBLICATION TRENDS FOR LATERAL FLOW ASSAYS 63
FIGURE 18 GLOBAL PATENT PUBLICATION TRENDS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2016–2021 64
5.7.2 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 64
FIGURE 19 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LATERAL FLOW ASSAYS COMPONENTS, 2016–2021 64
5.8 VALUE CHAIN ANALYSIS 65
5.9 REGULATORY LANDSCAPE 66
TABLE 3 REGULATORY STANDARDS/APPROVALS REQUIRED FOR LATERAL FLOW IMMUNOASSAY PRODUCTS, BY COUNTRY/REGION 66
5.9.1 NORTH AMERICA 66
5.9.2 EUROPE 67
5.9.3 ASIA PACIFIC 67
5.9.3.1 India 67
5.9.3.2 China 67
5.9.3.3 Japan 68
5.10 TECHNOLOGY ANALYSIS 69
5.10.1 KEY TECHNOLOGY: LATERAL FLOW ASSAYS 69
5.11 KEY CONFERENCES & EVENTS DURING 2021–2023 69
TABLE 4 LATERAL FLOW ASSAY COMPONENTS MARKET: DETAILED LIST OF CONFERENCES & EVENTS 69
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 70
5.12.1 KEY STAKEHOLDERS IN THE BUYING PROCESS 70
FIGURE 20 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
TABLE 5 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
5.12.2 BUYING CRITERIA 71
FIGURE 21 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
TABLE 6 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
5.13 PORTER’S FIVE FORCES ANALYSIS 72
TABLE 7 LATERAL FLOW ASSAY COMPONENTS MARKET:
PORTER’S FIVE FORCES ANALYSIS 72
5.13.1 THREAT FROM NEW ENTRANTS 72
5.13.2 THREAT FROM SUBSTITUTES 72
5.13.3 BARGAINING POWER OF BUYERS 73
5.13.4 BARGAINING POWER OF SUPPLIERS 73
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 73
6 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE 74
6.1 INTRODUCTION 75
TABLE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 75
6.2 MEMBRANES 75
TABLE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE,
2020–2027 (USD MILLION) 76
TABLE 10 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 76
6.2.1 NITROCELLULOSE MEMBRANES 77
6.2.1.1 Advantages of nitrocellulose membranes such as high protein-binding affinity and compatibility with a wide range of detection methods to drive market growth 77
TABLE 11 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 12 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (1 X 1 M SHEETS), BY REGION, 2020–2027 (IN THOUSANDS) 78
TABLE 13 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (20 MM X 1 M ROLLS), BY REGION, 2020–2027 (IN MILLIONS) 78
6.2.2 OTHER MEMBRANES 78
TABLE 14 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 79
6.3 PADS 80
TABLE 15 EXAMPLES OF DIFFERENT MATERIALS USED IN MANUFACTURING LATERAL FLOW ASSAY PADS 80
TABLE 16 LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 80
TABLE 17 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PADS, BY COUNTRY, 2020–2027 (USD MILLION) 81
6.3.1 SAMPLE PADS 81
6.3.1.1 Ability to promote even and controlled distribution of samples to drive market growth 81
TABLE 18 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SAMPLE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 82
6.3.2 CONJUGATE PADS 82
6.3.2.1 Conjugate pads play an important role in controlling the performance of lateral flow immunoassays 82
TABLE 19 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CONJUGATE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 83
6.3.3 ABSORBENT PADS 84
6.3.3.1 Absorbent pads prevent backflow—a key factor driving market growth 84
TABLE 20 LATERAL FLOW ASSAY COMPONENTS MARKET FOR ABSORBENT PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 84
6.4 OTHER COMPONENTS 84
TABLE 21 OTHER LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 85
7 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION 86
7.1 INTRODUCTION 87
TABLE 22 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 87
7.2 CLINICAL TESTING 87
TABLE 23 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 24 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 88
7.2.1 INFECTIOUS DISEASE TESTING 89
7.2.1.1 Rising demand for infectious disease testing in emerging markets to drive market growth 89
TABLE 25 LATERAL FLOW ASSAY COMPONENTS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 89
7.2.2 PREGNANCY & FERTILITY TESTING 90
7.2.2.1 Growing infertility levels due to changing lifestyles—a key factor driving market growth 90
TABLE 26 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PREGNANCY & FERTILITY TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 90
7.2.3 CARDIAC MARKER TESTING 91
7.2.3.1 Rising prevalence of cardiovascular diseases and growing government support to drive growth in this market segment 91
TABLE 27 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CARDIAC MARKER TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 92
7.2.4 CHOLESTEROL TESTING/LIPID PROFILING 92
7.2.4.1 Growing prevalence of obesity and CVD—
a key factor driving market growth 92
TABLE 28 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CHOLESTEROL TESTING/LIPID PROFILING, BY COUNTRY, 2020–2027 (USD MILLION) 93
7.2.5 DRUGS-OF-ABUSE TESTING 93
7.2.5.1 Technological advancements and a growing focus on workplace
drug testing are driving market growth 93
TABLE 29 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUGS-OF-ABUSE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 94
7.2.6 OTHER CLINICAL TESTING APPLICATIONS 94
TABLE 30 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER CLINICAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 95
7.3 VETERINARY DIAGNOSTICS 95
7.3.1 INFECTIOUS DISEASE OUTBREAKS (PARTICULARLY IN LARGE LIVESTOCK ANIMALS) TO DRIVE MARKET GROWTH 95
TABLE 31 LATERAL FLOW ASSAY COMPONENTS MARKET FOR VETERINARY DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 96
7.4 FOOD SAFETY & ENVIRONMENTAL TESTING 96
7.4.1 HIGH SENSITIVITY AND EASE OF USE ARE KEY FACTORS DRIVING THE DEMAND FOR LATERAL FLOW ASSAYS FOR FOOD SAFETY TESTING 96
TABLE 32 LATERAL FLOW ASSAY COMPONENTS MARKET FOR FOOD SAFETY & ENVIRONMENTAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
7.5 DRUG DEVELOPMENT & QUALITY TESTING 97
7.5.1 INCREASING FOCUS ON PRODUCT SAFETY AND QUALITY ASSURANCE TO DRIVE MARKET GROWTH IN THE COMING YEARS 97
TABLE 33 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUG DEVELOPMENT & QUALITY TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 98
8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE 99
8.1 INTRODUCTION 100
TABLE 34 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 100
8.2 SANDWICH ASSAYS 100
8.2.1 SANDWICH ASSAYS PROVIDE HIGHER LEVELS OF ASSAY SENSITIVITY AND SPECIFICITY THAN OTHER ASSAY TECHNIQUES—A KEY FACTOR DRIVING GROWTH IN THIS MARKET SEGMENT 100
TABLE 35 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SANDWICH ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 101
8.3 COMPETITIVE ASSAYS 101
8.3.1 REDUCED SELECTIVITY AND SENSITIVITY OF COMPETITIVE ASSAYS IN RELATION TO SANDWICH ASSAYS COULD HAMPER MARKET GROWTH 101
TABLE 36 LATERAL FLOW ASSAY COMPONENTS MARKET FOR COMPETITIVE ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 102
8.4 MULTIPLEX DETECTION ASSAYS 102
8.4.1 INCREASING ADOPTION OF MULTI-ANALYTE ASSAYS AMONG CLINICIANS TO DRIVE MARKET GROWTH 102
TABLE 37 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MULTIPLEX DETECTION ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION) 103
9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER 104
9.1 INTRODUCTION 105
TABLE 38 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 105
9.2 MEDICAL DEVICE MANUFACTURING COMPANIES 105
9.2.1 INCREASING USE OF POC TESTS IS DRIVING THE ADOPTION OF LATERAL FLOW ASSAY COMPONENTS AMONG MEDICAL DEVICE MANUFACTURING COMPANIES 105
TABLE 39 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE MANUFACTURING COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 106
9.3 MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES 106
9.3.1 GROWING INCLINATION TOWARD FAST AND EARLY DIAGNOSIS, ESPECIALLY IN RELATION TO THE CURRENT COVID-19 SCENARIO, WILL DRIVE MARKET GROWTH 106
TABLE 40 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES, BY COUNTRY,
2020–2027 (USD MILLION) 107
 
10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION 108
10.1 INTRODUCTION 109
FIGURE 22 CHINA TO REGISTER THE HIGHEST GROWTH IN THE LATERAL FLOW ASSAY COMPONENTS MARKET DURING THE FORECAST PERIOD 109
TABLE 41 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION,
2020–2027 (USD MILLION) 110
10.2 NORTH AMERICA 110
TABLE 42 NORTH AMERICA: MACROECONOMIC INDICATORS 110
FIGURE 23 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 111
TABLE 43 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 44 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 45 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 112
TABLE 46 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 113
TABLE 47 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 113
TABLE 48 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 49 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 114
TABLE 50 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 115
10.2.1 US 115
10.2.1.1 Increasing R&D investments and venture capital funding from both large and small firms towards the development of lateral flow assay diagnostics to drive market growth in the US 115
TABLE 51 US: MACROECONOMIC INDICATORS 116
TABLE 52 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 116
TABLE 53 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 116
TABLE 54 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 117
TABLE 55 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 117
TABLE 56 US: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 57 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 118
TABLE 58 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 119
10.2.2 CANADA 119
10.2.2.1 Lateral flow assay components market in Canada is estimated to grow at a relatively lower rate than the US 119
TABLE 59 CANADA: MACROECONOMIC INDICATORS 119
TABLE 60 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 120
TABLE 61 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 120
TABLE 62 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 120
TABLE 63 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 64 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 65 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 122
TABLE 66 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 122
10.3 EUROPE 122
TABLE 67 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 68 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 123
TABLE 69 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 123
TABLE 70 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 124
TABLE 71 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 124
TABLE 72 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 73 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 125
TABLE 74 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 126
10.3.1 GERMANY 126
10.3.1.1 Growing demand for POC testing to drive the lateral flow assay components market in Germany 126
TABLE 75 GERMANY: MACROECONOMIC INDICATORS 126
TABLE 76 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 127
TABLE 77 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 127
TABLE 78 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 127
TABLE 79 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 80 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 81 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 129
TABLE 82 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 129
10.3.2 FRANCE 129
10.3.2.1 High prevalence of age-related chronic diseases and infectious diseases to drive market growth in France 129
TABLE 83 FRANCE: MACROECONOMIC INDICATORS 130
TABLE 84 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 130
TABLE 85 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 130
TABLE 86 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 131
TABLE 87 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
TABLE 88 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 89 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 132
TABLE 90 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 133
10.3.3 UK 133
10.3.3.1 Severe impact of the second wave of COVID-19 in the first half of 2021 resulted in higher adoption of rapid COVID tests in the UK 133
TABLE 91 UK: MACROECONOMIC INDICATORS 134
TABLE 92 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 134
TABLE 93 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 134
TABLE 94 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 135
TABLE 95 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 135
TABLE 96 UK: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 97 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 136
TABLE 98 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 137
10.3.4 ITALY 137
10.3.4.1 Growing initiatives towards decentralization of medical services in Italy are contributing to the market growth in the country 137
TABLE 99 ITALY: MACROECONOMIC INDICATORS 137
TABLE 100 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 138
TABLE 101 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 138
TABLE 102 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 138
TABLE 103 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 139
TABLE 104 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 105 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 140
TABLE 106 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 140
10.3.5 SPAIN 140
10.3.5.1 Increasing focus of international organizations and domestic players on the development of POC products in the country to drive market growth 140
TABLE 107 SPAIN: MACROECONOMIC INDICATORS 141
TABLE 108 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 141
TABLE 109 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 142
TABLE 110 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 142
TABLE 111 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 142
TABLE 112 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 113 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 143
TABLE 114 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 144
10.3.6 REST OF EUROPE 144
TABLE 115 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 144
TABLE 116 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 145
TABLE 117 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 145
TABLE 118 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 145
TABLE 119 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 120 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 146
TABLE 121 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 147
10.4 ASIA PACIFIC 147
FIGURE 24 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 148
TABLE 122 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 149
TABLE 123 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 149
TABLE 124 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 149
TABLE 125 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 150
TABLE 126 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 150
TABLE 127 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 128 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 151
TABLE 129 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 152
10.4.1 CHINA 152
10.4.1.1 Higher exports of lateral flow assay components during the COVID-19 pandemic to drive market growth in the country 152
TABLE 130 CHINA: MACROECONOMIC INDICATORS 153
TABLE 131 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 153
TABLE 132 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 153
TABLE 133 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 154
TABLE 134 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 154
TABLE 135 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 155
TABLE 136 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 155
TABLE 137 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 156
10.4.2 JAPAN 156
10.4.2.1 Increasing prevalence of age-related illnesses driving the growth of the lateral flow assay components market in Japan 156
TABLE 138 JAPAN: MACROECONOMIC INDICATORS 157
TABLE 139 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 157
TABLE 140 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 157
TABLE 141 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 158
TABLE 142 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 158
TABLE 143 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 144 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 159
TABLE 145 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 160
10.4.3 INDIA 160
10.4.3.1 Increasing number of local manufacturers, growing healthcare concerns, and rising income levels to propel the growth of this market 160
TABLE 146 INDIA: MACROECONOMIC INDICATORS 160
TABLE 147 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 161
TABLE 148 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 161
TABLE 149 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 161
TABLE 150 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 162
TABLE 151 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 152 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 163
TABLE 153 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 163
10.4.4 AUSTRALIA 164
10.4.4.1 Increasing prevalence of infectious diseases, especially influenza, to drive the growth of the lateral flow assay components market in Australia 164
TABLE 154 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 164
TABLE 155 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 164
TABLE 156 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 165
TABLE 157 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 165
TABLE 158 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 166
TABLE 159 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 166
TABLE 160 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 167
10.4.5 REST OF ASIA PACIFIC 167
TABLE 161 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 167
TABLE 162 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 168
TABLE 163 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 168
TABLE 164 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 168
TABLE 165 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 169
TABLE 166 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 169
TABLE 167 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 170
 
10.5 LATIN AMERICA 170
10.5.1 HIGH DEMAND FOR HIV POC DEVICES IN THE REGION TO SUPPORT THE GROWTH OF THE MARKET 170
TABLE 168 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 169 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 171
TABLE 170 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD
TYPE, 2020–2027 (USD MILLION) 171
TABLE 171 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 172
TABLE 172 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 173 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 173
TABLE 174 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 173
10.6 MIDDLE EAST & AFRICA 173
10.6.1 SIGNIFICANT SUPPORT FROM GOVERNMENTS AND GLOBAL FIRMS TOWARDS EXPANDING HEALTHCARE SERVICES DRIVES THE ADOPTION OF LATERAL FLOW ASSAYS 173
TABLE 175 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 174
TABLE 176 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 174
TABLE 177 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 175
TABLE 178 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 175
TABLE 179 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 175
TABLE 180 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 181 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 176
TABLE 182 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 177
11 COMPETITIVE LANDSCAPE 178
11.1 OVERVIEW 178
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 178
FIGURE 25 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
11.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
FIGURE 26 REVENUE SHARE ANALYSIS FOR THE KEY PLAYERS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 180
11.4 MARKET SHARE ANALYSIS 180
FIGURE 27 LATERAL FLOW ASSAY COMPONENTS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 181
TABLE 183 LATERAL FLOW ASSAY COMPONENTS MARKET: DEGREE OF COMPETITION 182
11.5 R&D ASSESSMENT OF KEY PLAYERS 183
FIGURE 28 R&D EXPENDITURE: MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2018 VS. 2020 183
11.6 GEOGRAPHIC REVENUE ASSESSMENT OF KEY PLAYERS 183
FIGURE 29 GEOGRAPHIC REVENUE ASSESSMENT: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 184
11.7 COMPANY EVALUATION QUADRANT 184
11.7.1 STARS 184
11.7.2 PERVASIVE PLAYERS 184
11.7.3 EMERGING LEADERS 185
11.7.4 PARTICIPANTS 185
FIGURE 30 LATERAL FLOW ASSAY COMPONENTS MARKET: COMPANY EVALUATION MATRIX, 2021 185
11.8 COMPETITIVE BENCHMARKING 186
11.8.1 OVERALL COMPANY FOOTPRINT 186
TABLE 184 OVERALL COMPANY FOOTPRINT (17 COMPANIES) 186
TABLE 185 COMPANY FOOTPRINT: BY TYPE (17 COMPANIES) 187
TABLE 186 COMPANY FOOTPRINT: BY REGION (17 COMPANIES) 188
11.9 COMPETITIVE SCENARIO 188
11.9.1 DEALS 189
TABLE 187 DEALS, JANUARY 2019–FEBRUARY 2022 189
11.9.2 OTHER DEVELOPMENTS 189
TABLE 188 OTHER DEVELOPMENTS, JANUARY 2019–FEBRUARY 2022 189
12 COMPANY PROFILES 190
12.1 KEY PLAYERS 190
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 DANAHER CORPORATION (PALL CORPORATION AND CYTIVA LIFE SCIENCE) 190
TABLE 189 DANAHER CORPORATION: BUSINESS OVERVIEW 190
FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 191
12.1.2 SARTORIUS STEDIM BIOTECH 195
TABLE 190 SARTORIUS STEDIM BIOTECH: BUSINESS OVERVIEW 195
12.1.3 MERCK KGAA 199
TABLE 191 MERCK KGAA: BUSINESS OVERVIEW 199
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2020) 200
12.1.4 AHLSTROM-MUNKSJÖ 204
TABLE 192 AHLSTROM-MUNKSJÖ: BUSINESS OVERVIEW 204
FIGURE 34 AHLSTROM-MUNKSJÖ: COMPANY SNAPSHOT (2020) 205
12.1.5 ADVANCED MICRODEVICES PVT. LTD. 208
TABLE 193 ADVANCED MICRODEVICES PVT. LTD.: BUSINESS OVERVIEW 208
12.1.6 DCN DIAGNOSTICS 210
TABLE 194 DCN DIAGNOSTICS: BUSINESS OVERVIEW 210
12.2 OTHER PLAYERS 211
12.2.1 FORTIS LIFE SCIENCES 211
TABLE 195 FORTIS LIFE SCIENCES: BUSINESS OVERVIEW 211
12.2.2 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD 212
TABLE 196 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD.:
BUSINESS OVERVIEW 212
12.2.3 AXIVA SICHEM BIOTECH 214
TABLE 197 AXIVA SICHEM BIOTECH: BUSINESS OVERVIEW 214
12.2.4 NUPORE FILTRATION SYSTEM 216
TABLE 198 NUPORE FILTRATION SYSTEM: BUSINESS OVERVIEW 216
12.2.5 BALLYA BIO 217
TABLE 199 BALLYA BIO: BUSINESS OVERVIEW 217
12.2.6 RUNBIO BIOTECH CO. LTD. 219
TABLE 200 RUNBIO BIOTECH CO. LTD.: BUSINESS OVERVIEW 219
12.2.7 NEENAH GESSNER 220
TABLE 201 NEENAH GESSNER: BUSINESS OVERVIEW 220
12.2.8 MAXIM BIOMEDICAL 221
TABLE 202 MAXIM BIOMEDICAL: BUSINESS OVERVIEW 221
12.2.9 CYTODIAGNOSTICS 222
TABLE 203 CYTODIAGNOSTICS: BUSINESS OVERVIEW 222
12.2.10 SENOVA GMBH 223
TABLE 204 SENOVA GMBH: BUSINESS OVERVIEW 223
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 224
13.1 DISCUSSION GUIDE 224
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 229
13.3 AVAILABLE CUSTOMIZATIONS 231
13.4 RELATED REPORTS 231
13.5 AUTHOR DETAILS 232

US Healthcare Environmental Services Market by Type (Janitorial/Core-Cleaning, Infection Control & Prevention, Front-of-house cleaning & Brand Experie...

Publisher:        MarketsandMarkets

# of Pages:        126

Rating: 

1 User License $4,950

Publication Date:  March, 2022

Price:       $4,950 / User License




1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION & SCOPE 15
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 16
1.2.2 MARKET SEGMENTATION 16
FIGURE 1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET SEGMENTATION 16
1.2.3 YEARS CONSIDERED FOR THE STUDY 17
1.3 CURRENCY 17
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 17
1.4 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH APPROACH 19
FIGURE 2 RESEARCH DESIGN 19
2.1.1 SECONDARY RESEARCH 20
2.1.1.1 Key data from secondary sources 21
2.1.2 PRIMARY RESEARCH 21
FIGURE 3 PRIMARY SOURCES 22
2.1.2.1 Key data from primary sources 23
2.1.2.2 Insights from primary experts 23
2.1.2.3 Breakdown of primary interviews 24
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE (SUPPLY & DEMAND SIDE) AND DESIGNATION 24
2.2 MARKET SIZE ESTIMATION 25
FIGURE 5 MARKET SIZE APPROACH – REVENUE SHARE ANALYSIS 25
FIGURE 6 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 26
FIGURE 7 DEMAND-SIDE APPROACH 28
2.3 DATA TRIANGULATION 29
FIGURE 8 DATA TRIANGULATION METHODOLOGY 29
2.4 MARKET RANKING ANALYSIS 30
2.5 ASSUMPTIONS FOR THE STUDY 30
2.6 LIMITATIONS 31
2.6.1 METHODOLOGY-RELATED LIMITATIONS 31
2.6.2 SCOPE-RELATED LIMITATIONS 31
2.7 RISK ASSESSMENT 31
TABLE 2 RISK ASSESSMENT: US HEALTHCARE ENVIRONMENTAL SERVICES MARKET 31
 
3 EXECUTIVE SUMMARY 32
FIGURE 9 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 32
FIGURE 10 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET,
BY FACILITY TYPE, 2021 VS. 2026 (USD MILLION) 33
4 PREMIUM INSIGHTS 34
4.1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET OVERVIEW 34
FIGURE 11 STRINGENT REGULATORY GUIDELINES ON INFECTION CONTROL & PREVENTION METHODS IS A KEY FACTOR DRIVING THE MARKET GROWTH 34
4.2 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE AND FACILITY TYPE 35
FIGURE 12 JANITORIAL/CORE-CLEANING SERVICES ACCOUNTED FOR THE LARGEST SHARE OF THE US HEALTHCARE ENVIRONMENTAL SERVICES
MARKET IN 2020 35
4.3 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE (2021–2026) 36
FIGURE 13 ACUTE CARE FACILITIES TO DOMINATE THE US HEALTHCARE ENVIRONMENTAL SERVICES MARKET DURING THE FORECAST PERIOD 36
5 MARKET OVERVIEW 37
5.1 INTRODUCTION 37
5.2 MARKET DYNAMICS 37
TABLE 3 MARKET DYNAMICS: HEALTHCARE ENVIRONMENTAL SERVICES MARKET 37
5.2.1 MARKET DRIVERS 38
5.2.1.1 Increasing prevalence of Hospital-acquired infections (HAIs) 38
5.2.1.2 Rising number of hospital admissions and surgeries 39
TABLE 4 US: PERCENTAGE INCREASE IN THE NUMBER OF SURGERIES PERFORMED 39
FIGURE 14 TOTAL ADMISSIONS IN ALL US HOSPITALS 40
FIGURE 15 TOTAL NUMBER OF HOSPITALS IN THE US 40
5.2.1.3 Shortage of in-house expertise and the rising need to reduce healthcare costs 41
5.2.1.4 Increasing outsourcing of cleaning services 41
5.2.2 MARKET RESTRAINTS 41
5.2.2.1 Healthcare facilities with an in-house EVS department 41
5.2.3 MARKET OPPORTUNITIES 42
5.2.3.1 Sustained acquisitions among strategic & financial buyers 42
TABLE 5 COMPANY ACQUISITIONS 42
5.2.4 MARKET CHALLENGES 42
5.2.4.1 Noncompliance with cleaning standards by EVS providers 42
5.3 INDUSTRY TRENDS 43
5.3.1 EMERGENCE OF NEW SURFACE DISINFECTANTS &
GREEN CLEANING PRODUCTS 43
5.3.2 DISINFECTION ROBOTS 44
5.3.3 MONITORING TOOLS FOR CLEANING QUALITY ASSESSMENT 44
5.4 TECHNOLOGY ANALYSIS 45
TABLE 6 TECHNOLOGY INNOVATION IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 45
5.5 PATENT ANALYSIS 45
5.5.1 PATENT PUBLICATION TRENDS FOR HEALTHCARE ENVIRONMENTAL SERVICES 46
FIGURE 16 PATENT PUBLICATION TRENDS (JANUARY 2011–DECEMBER 2021) 46
5.5.2 JURISDICTION AND TOP APPLICANT ANALYSIS 47
FIGURE 17 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 47
FIGURE 18 TOP APPLICANT COUNTRIES/REGIONS FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 48
TABLE 7 LIST OF PATENTS/PATENT APPLICATIONS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET, 2020–2021 48
5.6 IMPACT OF COVID-19 ON THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 50
6 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE 51
6.1 INTRODUCTION 52
TABLE 8 US: HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 52
6.2 JANITORIAL SERVICES/CORE-CLEANING SERVICES 52
6.2.1 MANDATORY REGULAR CLEANING AND DISINFECTION OF HEALTHCARE FACILITIES TO DRIVE THE MARKET GROWTH 52
6.3 INFECTION PREVENTION & CONTROL SERVICES 53
TABLE 9 US: INFECTION PREVENTION & CONTROL SERVICE MARKET, BY TYPE,
2019–2026 (USD MILLION) 53
6.3.1 SPECIALIZED CLEANING SERVICES 53
6.3.1.1 Rising adoption of specialized services to reduce HAIs to drive the market growth 53
6.3.2 INFECTION PREVENTION & CONTROL CONSULTATION SERVICES 53
6.3.2.1 The provision of customized environmental services specific
to a healthcare facility ensures market demand 53
6.4 ENHANCED CLEANING TECHNOLOGY 54
6.4.1 RISING DEMAND FOR ADVANCED CLEANING SOLUTIONS TO DRIVE THE SEGMENT GROWTH 54
TABLE 10 EXAMPLES OF COMPANIES PROVIDING TECHNOLOGY & INNOVATION IN HEALTHCARE EVS 54
6.5 FRONT-OF-HOUSE CLEANING AND BRAND EXPERIENCE 56
6.5.1 RISING AWARENESS TOWARDS A CLEAN AND SAFE ENVIRONMENT DURING PANDEMICS TO SUSTAIN THE MARKET GROWTH 56
6.6 OTHER SERVICES 56
 
7 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE 57
7.1 INTRODUCTION 58
FIGURE 19 STATES WITH THE HIGHEST NUMBER OF COVID-19 ADMISSIONS
(FEBRUARY 2022) 58
TABLE 11 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE, 2019–2026 (USD MILLION) 59
7.2 ACUTE-CARE FACILITIES 59
TABLE 12 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR ACUTE-CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 59
7.2.1 ACUTE HOSPITALS 60
7.2.1.1 Increasing hospital admissions due to COVID-19 and the rising prevalence of HAIs propel the market growth 60
FIGURE 20 NUMBER OF HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS
IN THE US (2020) 60
FIGURE 21 HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS IN THE US (2020) 61
FIGURE 22 HAIS REPORTED BY CRITICAL ACCESS HOSPITALS (CAHS) IN THE US (2018) 61
7.2.2 MILITARY TREATMENT FACILITY 61
7.2.2.1 The increasing number of military ambulatory health services & funding to drive the market growth 61
FIGURE 23 MILITARY HEALTH SYSTEMS FACILITIES IN THE US (2021) 62
7.2.3 CHILDREN’S HOSPITALS 62
7.2.3.1 Rising cases of COVID-19 and infection-related mortality rates among children drive the market growth 62
7.2.4 AMBULATORY SURGERY CENTERS (ASCS) 63
7.2.4.1 ASCs save time and reduce the risk of HAIS; key factor driving the market growth 63
FIGURE 24 US SURGERY CASES BY SETTING: ASC VS. HOPD (2005-2020) 64
7.2.5 ACADEMIC MEDICAL CENTERS (AMCS) 64
7.2.5.1 Healthcare capacity expansion during COVID-19 drives the adoption of healthcare environmental services in AMCs 64
7.3 POST-ACUTE CARE FACILITIES 64
TABLE 13 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR POST-ACUTE CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 65
7.3.1 LONG-TERM ACUTE HOSPITALS (LTACH) 65
7.3.1.1 Increasing risk of infection due to prolonged hospital stays to drive the market growth 65
7.3.2 SKILLED NURSING FACILITIES (SNF) 66
7.3.2.1 Increasing admissions of elderly people in skilled nursing facilities to drive the market growth 66
7.3.3 OTHER POST-ACUTE CARE FACILITIES 66
7.4 NON-ACUTE CARE FACILITIES 67
TABLE 14 US: ENVIRONMENTAL SERVICES MARKET FOR NON-ACUTE CARE SETTINGS, BY TYPE, 2019–2026 (USD MILLION) 67
7.4.1 PHYSICIAN’S OFFICES AND CLINICS 67
7.4.1.1 High patient traffic leads to continuous cleaning & maintenance to drive the market growth 67
7.4.2 OTHER NON-ACUTE CARE FACILITIES 68
FIGURE 25 DISTRIBUTION OF INDUSTRY MEDICAL AND HEALTH R&D INVESTMENTS,
BY SEGMENT (2020) 68
8 COMPETITIVE LANDSCAPE 70
8.1 OVERVIEW 70
8.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 70
8.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 71
8.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 72
8.4 MARKET RANKING ANALYSIS 73
FIGURE 27 US HEALTHCARE ENVIRONMENTAL SERVICE MARKET RANKING,
BY KEY PLAYER, 2020 73
8.5 COMPETITIVE BENCHMARKING 75
TABLE 15 FOOTPRINT OF COMPANIES IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 75
TABLE 16 SERVICE FOOTPRINT OF COMPANIES 76
TABLE 17 END-USER FOOTPRINT OF COMPANIES 77
8.6 COMPETITIVE LEADERSHIP MAPPING 77
8.6.1 STARS 78
8.6.2 EMERGING LEADERS 78
8.6.3 PERVASIVE PLAYERS 78
8.6.4 PARTICIPANTS 78
FIGURE 28 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET:
COMPETITIVE LEADERSHIP MAPPING (2021) 79
8.7 COMPETITIVE SCENARIO 80
8.7.1 SERVICE APPROVALS/ENHANCEMENTS 80
8.7.2 DEALS 81
TABLE 19 DEALS, 2018–2022 81
8.7.3 OTHER DEVELOPMENTS 82
9 COMPANY PROFILES 83
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
9.1 SODEXO GLOBAL 83
TABLE 21 SODEXO GLOBAL: BUSINESS OVERVIEW 83
FIGURE 29 SODEXO GLOBAL: COMPANY SNAPSHOT (2021) 84
9.2 COMPASS GROUP (CROTHALL HEALTHCARE (US)) 87
TABLE 22 COMPASS GROUP: BUSINESS OVERVIEW 87
FIGURE 30 COMPASS GROUP: COMPANY SNAPSHOT (2021) 88
 
9.3 ARAMARK CORPORATION 90
TABLE 23 ARAMARK CORPORATION: BUSINESS OVERVIEW 90
FIGURE 31 ARAMARK CORPORATION: COMPANY SNAPSHOT (2021) 91
9.4 HOSPITAL HOUSEKEEPING SYSTEMS (HHS) (US) 94
TABLE 24 HOSPITAL HOUSEKEEPING SYSTEMS (HHS): BUSINESS OVERVIEW 94
9.5 HEALTHCARE SERVICES GROUP, INC. 97
TABLE 25 HEALTHCARE SERVICES GROUP, INC.: BUSINESS OVERVIEW 97
FIGURE 32 HEALTHCARE SERVICES GROUP: COMPANY SNAPSHOT (2020) 98
9.6 ABM INDUSTRIES INCORPORATED 100
TABLE 26 ABM INDUSTRIES INCORPORATED: BUSINESS OVERVIEW 100
FIGURE 33 ABM INDUSTRIES INCORPORATED: COMPANY SNAPSHOT (2020) 101
9.7 OCTOCLEAN 103
TABLE 27 OCTOCLEAN: BUSINESS OVERVIEW 103
9.8 SERVICEMASTER CLEAN (SERVICEMASTER TBS) 105
TABLE 28 SERVICEMASTER CLEAN.: BUSINESS OVERVIEW 105
9.9 CORVUS JANITORIAL SYSTEMS 107
TABLE 29 CORVUS JANITORIAL SYSTEMS: BUSINESS OVERVIEW 107
9.10 BRAVO! BUILDING SERVICES 109
TABLE 30 BRAVO! BUILDING SERVICES: BUSINESS OVERVIEW 109
9.11 POWERLINK ENVIRONMENTAL SERVICES, LLC 111
TABLE 31 POWERLINK ENVIRONMENTAL SERVICES, LLC: BUSINESS OVERVIEW 111
9.12 JANI-KING INTERNATIONAL, INC. 112
TABLE 32 JANI- KING INTERNATIONAL, INC: BUSINESS OVERVIEW 112
9.13 AVI FOOD SYSTEMS(US) 114
TABLE 33 AVI FOOD SYTEMS, INC.: BUSINESS OVERVIEW 114
9.14 SERVICON 115
TABLE 34 SERVICON: BUSINESS OVERVIEW 115
9.15 XANITOS, INC. 117
TABLE 35 XANITOS, INC.: BUSINESS OVERVIEW 117
9.16 STATHAKIS 119
TABLE 36 STATHAKIS: BUSINESS OVERVIEW 119
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
10 APPENDIX 120
10.1 INSIGHTS FROM INDUSTRY EXPERTS 120
10.2 DISCUSSION GUIDE 121
10.3 KNOWLEDGESTORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL 124
10.4 AVAILABLE CUSTOMIZATIONS 126
10.5 RELATED REPORTS 126
10.6 AUTHOR DETAILS 127